PuSH - Publication Server of Helmholtz Zentrum München: Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with <em>FLT3</em>-internal tandem duplication mutation (SORMAIN).

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Burchert, A.* ; Bug, G.* ; Fritz, L.V.* ; Finke, J.* ; Stelljes, M.* ; Röllig, C.* ; Wollmer, E.* ; Wäsch, R.* ; Bornhäuser, M.* ; Berg, T.* ; Lang, F.* ; Ehninger, G.* ; Serve, H.* ; Zeiser, R.* ; Wagner, E.M.* ; Kröger, N.* ; Wolschke, C.* ; Schleuning, M.* ; Götze, K.S.* ; Schmid, C.* ; Crysandt, M.* ; Eßeling, E.* ; Wolf, D.* ; Wang, Y.* ; Böhm, A.* ; Thiede, C.* ; Haferlach, T.* ; Michel, C.* ; Bethge, W.* ; Wündisch, T.* ; Brandts, C.* ; Harnisch, S.* ; Wittenberg, M.* ; Hoeffkes, H.G.* ; Rospleszcz, S. ; Burchardt, A.* ; Neubauer, A.* ; Brugger, M. ; Strauch, K. ; Schade-Brittinger, C.* ; Metzelder, S.K.*

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN).

J. Clin. Oncol. 38, 2993-3002 (2020)

Publ. Version/Full Text

DOI

PMC

	Closed

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT.PATIENTS AND METHODSIn a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40 placebo). Relapse-free survival (RFS) was the primary endpoint of this trial. Relapse was defined as relapse or death, whatever occurred first.RESULTS With a median follow-up of 41.8 months, the hazard ratio (HR) for relapse or death in the sorafenib group versus placebo group was 0.39 (95% CI, 0.18 to 0.85; log-rank P = .013). The 24-month RFS probability was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafenib (HR, 0.256; 95% CI, 0.10 to 0.65; log-rank P = .002). Exploratory data show that patients with undetectable minimal residual disease (MRD) before HCT and those with detectable MRD after HCT derive the strongest benefit from sorafenib.CONCLUSION Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

32.956

5.568

116